All In Biotech

Drug Trial Radar · NCT03794180

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

First-in-Human, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of TJ003234 (Anti-Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Monoclonal Antibody) in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Mar 18, 2019

Primary completion

Sep 5, 2019

Study completion Sep 5, 2019

Sponsor

Lead sponsor
I-Mab Biopharma US LimitedIndustry
Sponsor type
Industry
First posted
Jan 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

TJ003234RAR101 is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending dose study of TJ003234 in healthy adults to determine whether TJ003234 is safe and tolerated when administered as an intravenous (IV) infusion and to determine the maximum dose tolerated (MTD).

Conditions

  • Healthy Adult Subjects

Interventions

  • TJ003234Drug

    Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline

  • PlaceboDrug

    Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Profile: AEsTime frame: Up to 85 days after study drug administration
  2. Maximum Tolerated DoseTime frame: Up to 85 days after study drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.